

10/500245

Received 5, September 2003

DT04 Rec'd PCT/PTO 25 JUN 2004

A M E N D M E N T

(Amendment under the provisions of Art. 11 of the Law)

To: The Examiner, Ms. Miho OKAZAKI, of the Patent Office

1. Identification of the International Application

PCT/JP02/13858

2. Applicant

Name : NRL PHARMA, INC.  
Address: 2-1, Sakado 3-chome, Takatsu-ku,  
Kawasaki-shi, Kanagawa 213-0012 JAPAN  
Country of nationality : JAPAN  
Country of residence : JAPAN

3. Agent

Name : (8970) SHAMOTO, Ichio, Patent Attorney  
Address: YUASA AND HARA, Section 206, New Otemachi  
Bldg., 2-1, Otemachi 2-chome, Chiyoda-ku,  
Tokyo 100-0004 JAPAN

4. Item to be Amended Specification and Claims

5. Contents of the amendments

As shown in the attached sheets

At page 1, line 7 in the specification, "lactoferrin and the like" was amended to "(lactoferrin)". Since the active ingredient as described in the original claims is limited to lactoferrin alone, this amendment was made in agreement with this limitation.

At page 9, lines 9-10 in the specification, "processed to enteric coated preparations" and at the same page, lines 13-14, "enteric coated preparations of lactoferrin" were amended to "is made into pharmaceutical preparations" and "enteric coated preparations of lactoferrin", respectively. According to this amendment, as described in "Pharmaceutical Preparation 1" and "Pharmaceutical Preparation 2" at page 14 of the original specification, the pharmaceutical preparation of the invention of this application include, for example, tablets and capsules in addition to enteric coated preparations, and accordingly are not limited to enteric coated preparations.

In the description at page 10, line 21 to page 13, line

1 in the specification, the description relating to the components other than lactoferrin was deleted. Since the active ingredient as described in the original claims is limited to lactoferrin alone, this amendment was made in agreement with this limitation.

At page 13, line 27 to page 14, line 6 in the specification, the contents of the description of Example 1 were added.

At page 14, line 8, line 15 and line 21 in the specification, by the insertion of "in the same experiment as in Figure 1", it was clarified that each Figure is Figure 1 relating to the same experiment as in Figure 1.

In the description at page 16, lines 2 to 26 in the specification, the description relating to the components other than lactoferrin was deleted. Since the active ingredient as described in the original claims is limited to lactoferrin alone, this amendment was made in agreement with this limitation. Further, exemplification relating to lactoferrin was added.

The description in parentheses at page 18, lines 7 to 9 in the specification was deleted. Since the active ingredient as described in the original claims is limited to lactoferrin alone, this amendment was made in agreement with this limitation.

"zein" at page 20, line 3 in the specification was unnecessary, and accordingly deleted. Further "enteric coated tablets of lactoferrin" at page 20, line 13 in the specification was amended to "lactoferrin". According to this amendment, as described in "Pharmaceutical Preparation 1" and "Pharmaceutical Preparation 2" at page 14 of the original specification, the pharmaceutical preparations of the invention of this application include, for example, tablets and capsules in addition to enteric coated preparations, and accordingly are not limited to enteric coated preparations.

"Preparation Example 5" at page 21, line 1, page 24, line 26, Page 27, line 25, page 28, line 9, and line 24, page 29, line 4 and line 20, page 30, line 10, page 31, line 1 and line 11 and page 33, line 13 and line 28 in the specification was amended to "Preparation Example 3". This amendment was made because of the deletion of the original Preparation Examples 3 and 4, and the number of the original Preparation Example 5 was moved up.

One of "of" in "of of obese persons or the like" at page 13, line 24 in the specification is redundant, and accordingly was amended to "of obese persons or the like".

Preparation Examples 3 and 4 as described at page 24, lines 9 to 25 in the specification were deleted. The original Preparation Examples 3 and 4 were Preparation Examples relating to conalbumin, and since the active ingredient as

described in the original claims is limited to lactoferrin alone in this Amendment, the Preparation Example relating to conalbumin became unnecessary in this amendment.

"mevalotin" at page 29, line 12 and page 30, line 24 was amended to "pravastatin". This amendment was made because the original description "mevalotin" was merely an error, and accordingly the error was corrected.

In claims 1 to 3 (at page 35) and claims 9 to 11 (at page 37 to page 38), "at least one kind to be selected from the group consisting of a lactoferrin group protein comprising lactoferrin and conalbumin and an enzymatically decomposed product of the lactoferrin group protein comprising peptides corresponding to lactoferricin and lactoferricin of conalbumin" was limited to "lactoferrin".

Since claim 8 is an invention relating to a production method, "said composition" at the end of Japanese claim 8 was corrected to "said production method".

In claims 17 to 19 (at page 39 to page 40), "at least one kind to be selected from the group consisting of a lactoferrin group protein comprising lactoferrin and conalbumin and an enzymatically decomposed product of the lactoferrin group protein comprising peptides corresponding to lactoferricin and lactoferricin of conalbumin" was limited to "lactoferrin".

#### 6. List of Attached Documents

Pages 1, 9 - 16, 18, 20 - 21, 24 - 25, 27 - 31  
and 33 of the specification

Pages 35 - 40 of the claims